scholarly journals Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data

2017 ◽  
Author(s):  
Xinguo Lu ◽  
Jibo Lu ◽  
Bo Liao ◽  
Keqin Li
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Drug Response ◽  
Somatic Mutations ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Driver Genes ◽  
Mutation Matrix ◽  
Driving Pattern ◽  
Gene Modules

The multiple types of high throughput genomics data create a potential opportunity to identify driver pattern in ovarian cancer, which will acquire some novel and clinical biomarkers for appropriate diagnosis and treatment to cancer patients. However, it is a great challenging work to integrate omics data, including somatic mutations, Copy Number Variations (CNVs) and gene expression profiles, to distinguish interactions and regulations which are hidden in drug response dataset of ovarian cancer. To distinguish the candidate driver genes and the corresponding driving pattern for resistant and sensitive tumor from the heterogeneous data, we combined gene co-expression modules and mutation modulators and proposed the identification driver patterns method. Firstly, co-expression network analysis is applied to explore gene modules for gene expression profiles via weighted correlation network analysis (WGCNA). Secondly, mutation matrix is generated by integrating the CNVs and somatic mutations, and a mutation network is constructed from this mutation matrix. The candidate modulators are selected from the significant genes by clustering the vertex of the mutation network. At last, regression tree model is utilized for module networks learning in which the achieved gene modules and candidate modulators are trained for the driving pattern identification and modulator regulatory exploring. Many of the candidate modulators identified are known to be involved in biological meaningful processes associated with ovarian cancer, which can be regard as potential driver genes, such as CCL11, CCL16, CCL18, CCL23, CCL8, CCL5, APOB, BRCA1, SLC18A1, FGF22, GADD45B, GNA15, GNA11 and so on, which can help to facilitate the discovery of biomarkers, molecular diagnostics, and drug discovery.

scholarly journals Integrating Genetic and Transcriptomic Data to Reveal Pathogenesis and Prognostic Markers of Pancreatic Adenocarcinoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Kaisong Bai ◽  
Tong Zhao ◽  
Yilong Li ◽  
Xinjian Li ◽  
Zhantian Zhang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Pancreatic Adenocarcinoma ◽  
Somatic Mutation ◽  
Somatic Mutations ◽  
Prognostic Markers ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Genomic Variation ◽  
The Cancer Genome Atlas ◽  
Driver Genes

Pancreatic adenocarcinoma (PAAD) is one of the deadliest malignancies and mortality for PAAD have remained increasing under the conditions of substantial improvements in mortality for other major cancers. Although multiple of studies exists on PAAD, few studies have dissected the oncogenic mechanisms of PAAD based on genomic variation. In this study, we integrated somatic mutation data and gene expression profiles obtained by high-throughput sequencing to characterize the pathogenesis of PAAD. The mutation profile containing 182 samples with 25,470 somatic mutations was obtained from The Cancer Genome Atlas (TCGA). The mutation landscape was generated and somatic mutations in PAAD were found to have preference for mutation location. The combination of mutation matrix and gene expression profiles identified 31 driver genes that were closely associated with tumor cell invasion and apoptosis. Co-expression networks were constructed based on 461 genes significantly associated with driver genes and the hub gene FAM133A in the network was identified to be associated with tumor metastasis. Further, the cascade relationship of somatic mutation-Long non-coding RNA (lncRNA)-microRNA (miRNA) was constructed to reveal a new mechanism for the involvement of mutations in post-transcriptional regulation. We have also identified prognostic markers that are significantly associated with overall survival (OS) of PAAD patients and constructed a risk score model to identify patients’ survival risk. In summary, our study revealed the pathogenic mechanisms and prognostic markers of PAAD providing theoretical support for the development of precision medicine.

scholarly journals Biological Insights into Chemotherapy Resistance in Ovarian Cancer

2019 ◽  
Vol 20 (9) ◽  
pp. 2131 ◽  
Author(s):  
Michelle A. Glasgow ◽  
Peter Argenta ◽  
Juan E. Abrahante ◽  
Mihir Shetty ◽  
Shobhana Talukdar ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Expression Profiles ◽  
Rna Extraction ◽  
Chemotherapy Resistance ◽  
Gene Expression Profiles ◽  
Gene Set Enrichment Analysis ◽  
Before And After ◽  
Tumor Gene Expression ◽  
Tumor Gene

The majority of patients with high-grade serous ovarian cancer (HGSOC) initially respond to chemotherapy; however, most will develop chemotherapy resistance. Gene signatures may change with the development of chemotherapy resistance in this population, which is important as it may lead to tailored therapies. The objective of this study was to compare tumor gene expression profiles in patients before and after treatment with neoadjuvant chemotherapy (NACT). Tumor samples were collected from six patients diagnosed with HGSOC before and after administration of NACT. RNA extraction and whole transcriptome sequencing was performed. Differential gene expression, hierarchical clustering, gene set enrichment analysis, and pathway analysis were examined in all of the samples. Tumor samples clustered based on exposure to chemotherapy as opposed to patient source. Pre-NACT samples were enriched for multiple pathways involving cell cycle growth. Post-NACT samples were enriched for drug transport and peroxisome pathways. Molecular subtypes based on the pre-NACT sample (differentiated, mesenchymal, proliferative and immunoreactive) changed in four patients after administration of NACT. Multiple changes in tumor gene expression profiles after exposure to NACT were identified from this pilot study and warrant further attention as they may indicate early changes in the development of chemotherapy resistance.

scholarly journals Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Lucas Delmonico ◽  
Said Attiya ◽  
Joan W. Chen ◽  
John C. Obenauer ◽  
Edward C. Goodwin ◽  
...  
Keyword(s):  
Gene Expression ◽  
Expression Profiles ◽  
Pearson Correlation ◽  
Gene Expression Profiles ◽  
Standard Operating Procedure ◽  
Driver Genes ◽  
Technology Platforms ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Rna Biomarkers

Background. With the development of new drug combinations and targeted treatments for multiple types of cancer, the ability to stratify categories of patient populations and to develop companion diagnostics has become increasingly important. A panel of 325 RNA biomarkers was selected based on cancer-related biological processes of healthy cells and gene expression changes over time during nonmalignant epithelial cell organization. This “cancer in reverse” approach resulted in a panel of biomarkers relevant for at least 7 cancer types, providing gene expression profiles representing key cellular signaling pathways beyond mutations in “driver genes.” Objective. To further investigate this biomarker panel, the objective of the current study is to (1) validate the assay reproducibility for the 325 RNA biomarkers and (2) compare gene expression profiles side by side using two technology platforms. Methods and Results. We have mapped the 325 RNA transcripts and in a custom NanoString nCounter expression panel to be compared to all potential probe sets in the Affymetrix Human Genome U133 Plus 2.0. The experiments were conducted with 10 unique biological formalin-fixed paraffin-embedded (FFPE) breast tumor samples. Each site extracted RNA from four sections of 10-micron thick FFPE tissue over three different days by two different operators using an optimized standard operating procedure and quality control criteria. Samples were analyzed using mas5 in BioConductor and NanoStringNorm in R. Pearson correlation showed reproducibility between sites for all 60 samples with r=0.995 for Affymetrix and r=0.999 for NanoString. Correlation in multiple days and multiple users was for Affymetrix r=0.962−0.999 and for NanoString r=0.982−0.991. Conclusion. The 325 RNA biomarkers showed reproducibility in two technology platforms with moderate to high concordance. Future directions include performing clinical validation studies and generating rationale for patient selection in clinical trials using the technically validated assay.

scholarly journals Independent Test Set Performance in the Prediction of Early Relapse in Ovarian Cancer with Gene Expression Profiles

2005 ◽  
Vol 11 (21) ◽  
pp. 7958-7959 ◽  
Author(s):  
Frank De Smet ◽  
Nathalie L.M.M. Pochet ◽  
Bart L.R. De Moor ◽  
Toon Van Gorp ◽  
Dirk Timmerman ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Test Set ◽  
Early Relapse ◽  
Independent Test

Abstract 1867: Gene expression profiles obtained fromex vivohuman scalp hair to determine the effects of drug response following exposure to HDAC inhibitors.

2012 ◽  
Author(s):  
Benjamin J. Reed ◽  
Ann Forslund ◽  
Tineke Casneuf ◽  
Gino Miele ◽  
Emma Grimes ◽  
...  
Keyword(s):  
Gene Expression ◽  
Drug Response ◽  
Scalp Hair ◽  
Expression Profiles ◽  
Hdac Inhibitors ◽  
Gene Expression Profiles

scholarly journals Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1247 ◽  
Author(s):  
David G.J. Cucchi ◽  
Costa Bachas ◽  
Marry M. van den Heuvel-Eibrink ◽  
Susan T.C.J.M. Arentsen-Peters ◽  
Zinia J. Kwidama ◽  
...  
Keyword(s):  
Gene Expression ◽  
Drug Resistance ◽  
Drug Response ◽  
Molecular Mechanisms ◽  
Ex Vivo ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Leukemic Cells ◽  
Treatment Optimization ◽  
Pediatric Aml

Novel treatment strategies are of paramount importance to improve clinical outcomes in pediatric AML. Since chemotherapy is likely to remain the cornerstone of curative treatment of AML, insights in the molecular mechanisms that determine its cytotoxic effects could aid further treatment optimization. To assess which genes and pathways are implicated in tumor drug resistance, we correlated ex vivo drug response data to genome-wide gene expression profiles of 73 primary pediatric AML samples obtained at initial diagnosis. Ex vivo response of primary AML blasts towards cytarabine (Ara C), daunorubicin (DNR), etoposide (VP16), and cladribine (2-CdA) was associated with the expression of 101, 345, 206, and 599 genes, respectively (p < 0.001, FDR 0.004–0.416). Microarray based expression of multiple genes was technically validated using qRT-PCR for a selection of genes. Moreover, expression levels of BRE, HIF1A, and CLEC7A were confirmed to be significantly (p < 0.05) associated with ex vivo drug response in an independent set of 48 primary pediatric AML patients. We present unique data that addresses transcriptomic analyses of the mechanisms underlying ex vivo drug response of primary tumor samples. Our data suggest that distinct gene expression profiles are associated with ex vivo drug response, and may confer a priori drug resistance in leukemic cells. The described associations represent a fundament for the development of interventions to overcome drug resistance in AML, and maximize the benefits of current chemotherapy for sensitive patients.

scholarly journals Comparative Transcriptome Analysis of Different Dendrobium Species Reveals Active Ingredients-Related Genes and Pathways

2020 ◽  
Vol 21 (3) ◽  
pp. 861 ◽  
Author(s):  
Yingdan Yuan ◽  
Bo Zhang ◽  
Xinggang Tang ◽  
Jinchi Zhang ◽  
Jie Lin
Keyword(s):  
Gene Expression ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Rna Seq ◽  
Active Ingredients ◽  
Hub Genes ◽  
Transcriptome Database ◽  
Gene Modules ◽  
Functional Investigation ◽  
First Time

Dendrobium is widely used in traditional Chinese medicine, which contains many kinds of active ingredients. In recent years, many Dendrobium transcriptomes have been sequenced. Hence, weighted gene co-expression network analysis (WGCNA) was used with the gene expression profiles of active ingredients to identify the modules and genes that may associate with particular species and tissues. Three kinds of Dendrobium species and three tissues were sampled for RNA-seq to generate a high-quality, full-length transcriptome database. Based on significant changes in gene expression, we constructed co-expression networks and revealed 19 gene modules. Among them, four modules with properties correlating to active ingredients regulation and biosynthesis, and several hub genes were selected for further functional investigation. This is the first time the WGCNA method has been used to analyze Dendrobium transcriptome data. Further excavation of the gene module information will help us to further study the role and significance of key genes, key signaling pathways, and regulatory mechanisms between genes on the occurrence and development of medicinal components of Dendrobium.

Gene expression profiles that predict response to platinum and identify patterns of pathway deregulation in advanced ovarian cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 5031-5031
Author(s):  
J. M. Lancaster ◽  
A. Bild ◽  
J. Pittman ◽  
R. Sayer ◽  
R. S. Whitaker ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Advanced Ovarian Cancer ◽  
Pathway Deregulation
Sign in / Sign up

Export Citation Format

Share Document